Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer

Journal of Urology

Volumn 159, Issue 1, 1998, Pages 5-12

  Woodrum, David L ^b   Brawer, Michael K ^b   Partin, Alan W ^b   Catalona, William J ^b   Southwick, Paula C ^a  

^a Hybritech Incorporated   (United States)

^b NONE

Author keywords

Clinical protocols; Clinical trials; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; COST BENEFIT ANALYSIS; FINGER; HUMAN; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROBABILITY; PROSTATE BIOPSY; PROSTATE CANCER; RECTUM; REVIEW; STATISTICAL ANALYSIS; TUMOR VOLUME;

EID: 0031986360     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63996-X     Document Type: Review

References (65)

1. Kuriyama, M., Wang, M. C., Lee, C. L., Killian, C. S., Papsidero, L. D., Inaji, H., Loor, R. M., Lin, M. F., Nishiura, T., Slack, N. H., Murphy, G. P. and Chu, T. M.: Multiple marker evaluation in prostate cancer with the use of tissue-specific antigens. J. Natl. Cancer Inst., 68: 99, 1982.
2. Pontes, J. E., Chu, T. M., Slack, N., Karr, J. and Murphy, G. P.: Serum prostatic antigen measurement in localized prostatic cancer: correlation with clinical course. J. Urol., 128: 1216, 1982.
3. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med., 317: 909, 1987.
4. Cooner, W. H., Mosely, B. R., Rutherford, C. L., Jr., Beard, J. H., Pond, H. S., Terry, W. J., Igel, T. C. and Kidd, D. D.: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J. Urol., 143: 1146, 1990.
5. Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J., Petros, J. A. and Andriole, G. L.: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Engl. J. Med., 324: 1156, 1991.
6. Brawer, M. K., Chetner, M. P., Beatie, J., Buchner, D. M., Vessella, R. L. and Lange, P. H.: Screening for prostate carcinoma with prostate specific antigen. J. Urol., 147: 841, 1992.
7. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Tremblay, M., Gomaz, J.-L. and Emond, J.: Serum prostate specific antigen as pre-screening test for prostate cancer. J. Urol., part 2, 147: 846, 1992.
8. Catalona, W. J., Smith, D. S., Ratliff, T. L. and Basler, J. W.: Detection of organ-confined prostate cancer is increased through prostate specific antigen-based screening. J.A.M.A., 270: 948, 1993.
9. Catalona, W. J., Richie, J. P., Ahmann, F. K., Hudson, M. A., Scardino, P. T., Flanigan, R. C., deKernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., Waters, W. B., MacFarlane, M. T. and Southwick, P. C.: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol., 151: 1283, 1994.
10. Christensson, A., Laurell, C. B. and Lilja, H.: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem., 194: 755, 1990.
11. Stenman, U. H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K. and Alfthan, O.: Complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res., 51: 222, 1991.
12. Christensson, A., Björk, T., Nilsson, O., Dahlén, U., Matikainen, M.-T., Cockett, A. T. K., Abrahamsson, P.-A. and Lilja, H.: Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J. Urol., 150: 100, 1993.
13. Luderer, A. A., Chen, Y.-T., Soriano, T. F., Kramp, W. J., Carlson, G., Cuny, C., Sharp, T., Smith, W., Petteway, J., Brawer, M. K. and Thiel, R.: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology, 46: 187, 1995.
14. Catalona, W. J., Smith, D. S., Wolfert, R., Wang, T. J., Rittenhouse, H., Ratliff, T. L. and Nadler, R. B.: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. J.A.M.A., 274: 1214, 1995.
15. Bangma, C. H., Kranse, R., Blijengerg, B. G. and Schröder, F. H.: The value of screening tests in the detection of prostate cancer. Results of a retrospective evaluation of 1726 men. Urology, 46: 773, 1995.
16. Bangma, C. H., Kranse, R., Blijengerg, B. G. and Schröder, F. H.: The value of screening tests in the detection of prostate cancer. Retrospective analysis of free/total prostate-specific antigen ratio, age-specific reference ranges, and PSA density. Urology, 46: 779, 1995.
17. Chen, Y. T., Luderer, A. A., Thiel, R. P., Carlson, G., Cuny, C. L. and Soriano, T. F.: Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology, 47: 518, 1996.
18. Prestigiacomo, A. F., Lilja, H., Pettersson, K., Wolfert, R. L. and Stamey, T. A.: A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J. Urol., 156: 350, 1996.
19. Elgamal, A.-A., Cornillie, F. J., Van Poppel, H. P., Van de Doore, W. M., McCabe, R. and Baert, L. V.: Free-to-total prostate specific antigen ratio as a single test for detection of significant Tic prostate cancer. J. Urol., 156: 1042, 1996.
20. Murphy, G. P., Barren, R. J., Erickson, S. J., Bowes, V. A., Wolfert, R. L., Bartsch, G., Klocker, H., Pointer, J., Reissigl, A., McLeod, D. G., Douglas, T., Morgan, T., Kenny, G. M., Ragde, H., Boynton, A. L. and Holmes, E. H.: Evaluation and comparison of two new prostate carcinoma markers. Free prostate specific antigen and prostate specific antigen membrane antigen. Cancer, 78: 809, 1996.
21. Van Cangh, P. J., De Nayer, P., Sauvage, P., Tombal, B., Eisen, M., Lorge, F., Opsomer, R. and Wese, F. X.: Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate, suppl., 7: 30, 1996.
22. Catalona, W. J., Smith, D. S. and Ornstein, D. K.: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination: enhancement of specificity with free PSA measurements. J.A.M.A., 277: 1452, 1997.
23. Partin, A. W., Catalona, W. J., Southwick, P. C., Subong, E. N., Gasior, G. H. and Chan, D. W.: Analysis of percent free prostate-specific antigen PSA for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology, suppl., 48: 55, 1996.
24. Oesterling, J. E. and Lilja, H.: Early detection and diagnosis. In: Comprehensive Textbook of Genitourinary Oncology. Edited by N. J. Vogelzang, P. T. Scardino, W. U. Shipley and D. S. Coffey. Baltimore: Williams & Wilkins, pp. 668-673, 1996.
25. Leinonen, J. and Stenman, U.-H.: Significance of free and bound prostate-specific antigen. Endocr. Related Ca, 3: 191, 1996.
26. Lilja, H.: Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin. Urol. Clin. N. Amer., 20: 681, 1993.
27. McCormack, R. T., Rittenhouse, H. G., Finlay, J. A., Sokoloff, R. L., Wang, T., Wolfert, R., Lilja, H. and Oesterling, J.: Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology, 45: 729, 1995.
28. van Iersel, M. P., Witjes, W. P., Thomas, C. M., Segers, M. F., Oosterhof, G. O. and Debruyne, F. M.: Review on the simultaneous detection of total prostate-specific antigen and free prostate-specific antigen. Prostate, suppl., 7: 48, 1996.
29. Catalona, W. J.: Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Prostate, suppl., 7: 65, 1996.
30. Partin, A. W. and Carter, H. B.: The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer. Urol. Clin. N. Amer., 23: 531, 1996.
31. Oesterling, J. E., Jacobsen, S. J., Klee, G. G., Pettersson, K., Piironen, T., Abrahamsson, P.-A., Stenman, U.-H., Dowell, B., Lövgren, T. and Lilja, H.: Free, complexed, and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J. Urol., 154: 1090, 1995.
32. Moul, J. W., Sesterhenn, I. A., Connelly, R. R., Douglas, T., Srivastava, S., Mostofi, F. K. and McLeod, D. G.: Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. J.A.M.A., 274: 1277, 1995.
33. Smith, D. S., Bullock, A. D., Catalona, W. J. and Herschman, J. D.: Racial differences in a prostate cancer screening study. J. Urol., 156: 1366, 1996.
34. Oesterling, J. E., Kumamoto, Y., Tsukamoto, T., Girman, C. J., Guess, H. A., Masumori, N., Jacobsen, S. J. and Lieber, M. M.: Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Brit. J. Urol., 75: 347, 1995.
35. Keetch, D. W., Catalona, W. J. and Smith, D. S.: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J. Urol., 151: 1571, 1994.
36. Arcangeli, C. G., Shepherd, D. L., Smith, D. S., Humphrey, P. A., Keetch, D. W. and Catalona, W. J.: Correlation of percent free PSA with pathologic features of prostate carcinomas. J. Urol., part 2, 155: 415A, abstract 420, 1996.
37. Carter, B. H., Partin, A. W., Luderer, A. A., Metter, E. J., Landis, P., Chan, D. W., Fozard, J. L. and Pearson, J. D.: Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology, 49: 379, 1997.
38. Lerner, S. E., Jacobsen, S. J., Lilja, H., Bergstralh, E. J., Ransom, J., Klee, G. G., Piironen, T., Blute, M. L., Lieber, M. M., Zincke, H., Pettersson, K., Peterson, D. and Oesterling, J. E.: Free, complexed, and total serum PSA concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology, 48: 240, 1996.
39. Hendricks, W. H., England, B. G., Giacherio, D. A. and Oesterling, J. E.: Free to total PSA ratio does not predict extraprostatic spread of prostatic adenocarcinoma. J. Urol., part 2, 155: 369A, abstract 236, 1996.
40. Graefen, M., Hammerer, P., Henke, P., Hilz, H., Huland, E. and Huland, H.: Percent of free PSA does not correlate with pathological outcome. J. Urol., part 2, 155: 369A, abstract 236, 1996.
41. Pannek, J., Subong, E. N., Jones, K. A., Marschke, P. L., Epstein, J. I., Chan, D. W., Carter, H. B., Luderer, A. A. and Partin, A. W.: The role of free/total PSA does not improve the prediction of final pathological stage for men with localized prostate cancer. Urology, suppl., 48: 51, 1996.
42. Marks, L. S., Dorey, F., Rhodes, T., Shery, E. D., Rittenhouse, H., Partin, A. W. and deKernion, J. B.: Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia. J. Urol., 156: 1035, 1996.
43. Aus, G., Gergdahl, S., Frösing, R., Lodding, P., Pileblad, E. and Hugosson, J.: Reference range of prostate-specific antigen after transurethral resection of the prostate. Urology, 47: 529, 1996.
44. Stenman, U.-H., Alfthan, H. and the Scandinavian BPH Study Group: Effect of long term treatment with finasteride on free and total PSA in serum. J. Urol., part 2, 155: 698A, abstract 1547, 1996.
45. Campo, R., Tchetgen, M. B. and Oesterling, J. E.: The effect of a short course of antibiotics on the serum PSA concentration. J. Urol., part 2, 155: 425A, abstract 459, 1996.
46. Yuan, J. J. J., Coplen, D. E., Petros, J. A., Figenshau, R. S., Ratliff, T. L., Smith, D. S. and Catalona, W. J.: Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J. Urol., 147: 810, 1992.
47. Ornstein, D. K., Rao, G. S., Smith, D. S., Ratliff, T. L., Basler, J. W. and Catalona, W. J.: Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. J. Urol., 157: 195, 1997.
48. Partin, A. W., Piantadosi, S., Subong, E. N., Kelley, C. A., Hortopan, S., Chan, D. W., Wolfert, R. L., Rittenhouse, H. G. and Carter, H. B.: Clearance rate of serum-free and total PSA following radical retropubic prostatectomy. Prostate, suppl., 7: 35, 1996.
49. Semjonow, A., Oberpenning, F., Surdel, W., Weining, C., Brandt, B., Brandau, W., Hertle, L. and Hamm, M.: Prostate-specific antigen and radical prostatectomy: variation after manipulation of the prostate and consecutive elimination half-life of free and total PSA. J. Urol., part 2, 155: 697A, abstract 1545, 1996.
50. Tchetgen, M.-B., Song, J. T., Strawderman, M., Jacobsen, S. J. and Oesterling, J. E.: Ejaculation increases the serum prostate-specific antigen concentration. Urology, 47: 511, 1996.
51. Herschman, J. D., Smith, D. S. and Catalona, W. J.: Effects of ejaculation on free and total PSA levels. J. Urol., part 2, 155: 423A, abstract 450, 1996.
52. Oremek, G. M. and Seiffert, U. B.: Physical activity releases prostate-specific antigen (PSA) from the prostate gland into blood and increases serum PSA concentrations. Clin. Chem., 42: 691, 1996.
53. Woodrum, D. L., French, C. and Shamel, L. B.: Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology, suppl., 48: 33, 1996.
54. Van der Horst, F. A. L., van Adrichem, N. P. H., Buitenhuis, A. and Stoevelaar, I.: Study on the stability of free PSA in sera. Clin. Chem., suppl., 42: 267, 1996.
55. Piironen, T., Pettersson, K., Suonpää, M., Stenman, U. H., Oesterling, J. E., Lövgren, T. and Lilja, H.: In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen complexed to alpha 1-antichymotrypsin in blood samples. Urology, suppl., 48: 81, 1996.
56. Graves, H. B.: Standardization of immunoassays for prostate-specific antigen. A problem of prostate-specific antigen complexation or a problem of assay design? Cancer, 72: 3141, 1993.
57. Wu, J. T.: Assay for prostate specific antigen (PSA): problems and possible solutions. J. Clin. Lab. Anal., 8: 51, 1994.
58. Semjonow, A., Burkhard, B., Oberpenning, F., Roth, S. and Hertle, L.: Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate, suppl., 7: 3, 1996.
59. Fortunato, A., Dorizzi, R. M., Marchi, G., Cocco, C. and Davini, C C. A.: fPSA/tPSA ratios obtained using nine commercial assays. Clin. Chem., suppl., 42: 268, 1996.
60. Jung, K., Stephan, C., Lein, M., Henke, W., Schnorr, D., Brux, B., Schürenkämper, P. and Loening, S. A.: Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin. Chem., 42: 1026, 1996.
61. Cuny, C., Pham, L., Kramp, W., Sharp, T. and Soriano, T.: Evaluation of a two-site immunoradiometric assay for measuring noncomplexed (free) prostate-specific antigen. Clin. Chem., 42: 1243, 1996.
62. Woodrum, D. L., French, C. F., Hill, T. M., Roman, S. J., Slatore, H. L., Shaffer, J. L., York, L. G., Eure, K. L., Loveland, K. G., Gasior, G. H., Southwick, P. C. and Shamel, L. B.: Analytical performance of the Tandem-R free PSA immune-assay measuring free prostate specific antigen. Clin. Chem., 43: 1203, 1997.
63. Pearson, J. D., Luderer, A. A., Metter, E. J., Partin, A. W., Chan, D. W., Fozard, J. L. and Carter, H. B.: Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology, suppl., 48: 4-9, 1996.
64. Littrup, P. J., Kane, R. A., Mettlin, C. J., Murphy, G. P., Lee, F., Toi, A., Badalament, R. and Babaian, R.: Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer, 74: 3146, 1994.
65. Littrup, P. J. and Goodman, A. C.: Economic considerations of prostate cancer: the role of detection specificity and biopsy reduction. Cancer, suppl., 75: 1987, 1995.